Welcome

You've successfully logged in

This website uses cookies to provide you with a more responsive and personalized service. In order to proceed to login, however, you must formally accept our cookie policy. Please read our cookie & privacy policies for more information.

NOTICE OF COOKIES: This website is operated by Roche Diagnostics Polska Sp. z o.o., ul. Wybrzeze Gdynskie 6B, 01-531 Warszawa, Poland. Roche uses cookies to collect personal data relating to you and your browsing activity in order to improve the website and your browsing experience. For more information on our use of cookies and how you can indicate your preferences regarding the use of cookies, see our cookie policy. You may indicate your willingness to accept the use of cookies here:

Your decision to opt-out of cookies may substantially limit your ability to navigate and use this website.

This part of the page requires cookies. Please click on "Accept" to proceed

NOTICE OF COOKIES: This website uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. Please read our cookie policy for more information on the cookies we use and how to delete or block them.

Introduction

The epidemic rise in obesity has generated large amounts of research into the factors underlying this complex disease as well as to mechanisms linking its metabolic and cardiovascular complications [1]. Recent data suggest that the endocannabinoid system is a key circuit contributing to central appetitive regulation and that its aberrant activation may contribute to obesity [2]. These findings have been corroborated by studies in which the cannabinoid receptor (CB1) has emerged as a possible target for the treatment of obesity [3].

We aimed at evaluating, by means of a genetic association research study, whether genetic variation at the cannabinoid receptor locus (CNR1) could have an effect on adiposity and fat distribution. The synonymous G/A single nucleotide polymorphism (SNP) at position 1422 of the CNR1 gene was selected because it resides in the gene's coding region (threonine at position 453).

Materials and Methods

For research purposes, 1064 research samples were collected from obese subjects, and 251 samples were collected from non-obese individuals for controls. G1422A (rs1049353) genotypes were determined by a commercial hydrolysis-probe based genotyping assay on the LightCycler® 480 System (Figure 1). Blank samples and samples with known genotype were included as negative and positive controls. We achieved 100% concordance in the analysis of duplicate samples. Statistical analyses were performed using SPSS software, version 12.0 (SPSS, Chicago, IL, USA). Linear regression was used to adjust anthropometric parameters for age and BMI.

Results and Discussion

The prevalence of the G1422A variant was not significantly different between cases and controls (OR=1.056; p=0.626). In obese men (but not women), homozygosity for the variant A allele was significantly associated with highest waist-to-hip ratio (WHR) and increased waist circumference (p=0.009 and p=0.008, respectively; values adjusted for age and body-mass-index). A trend for an association with increased fat mass was also observed (p=0.033).

Conclusions

Comparative anthropometric analysis of the samples of adult obese individuals stratified by gender revealed meaningful differences between the samples of obese men with distinct genotypes of the CNR1 G1422A variant. Under a recessive model, we found three significant associations in the same direction namely 1422A/A homozygotes are more abdominally obese, which could indicate that these are true associations. Our data indicate that the absence of a CNR1 gene with the G-allele at position 1422 might increases the risk for obesity in males. The fact that the associations were only seen in samples of obese men can potentially be explained by general gender specific discrepancies in eating-habitsand fat ingestion in particular. In conclusion, our data indicate that the G1422A polymorphism in the cannabinoid receptor-1 gene might be associated with increased abdominal adiposity in obese men.

Products are for life science research only. Not for use in diagnostic procedures unless otherwise indicated. This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.

Brafton Pop Up Page

Got an idea?

First Name

*

Last Name

*

Country

Country Name*

Phone Number?

*

Email

*

*Required Field

Text

What are you most curious to learn about? What would you like to ask our Roche Scientists?

*

Please subscribe me to the email newsletter for amazing content delivered right to my inbox.

Please subscribe me to the email newsletter for amazing content delivered right to my inbox.

Genomic Pop Up Page

Customer Publication Submission Form

Please complete the below form. Your paper(s) will be evaluated for placement on lifescience.roche.com.
Please separate multiple entries using comma.

First Name

*

Last Name

*

Email

*

Institution/Company, Country

*

What are the Roche products used in your paper?

*

PubMed ID and/or Journal Information

*

*Required Field

Your information has been successfully submitted.

Your Order Request has been successfully submitted.

Thank you for subscribing to our eNewsletter!

You will receive the Roche Newsletter for our new and exciting products and special offers.
You will hear about upcoming events, and download the latest technical and scientific literature. Your privacy is ensured.

CataLogNum Pop Up Page

You are being redirected to sigmaaldrich.com

Exclusive distribution agreement with Merck now in effect from Sep 1st 2017. The UPL ProbeLibrary products are now available exclusively on SigmaAldrich.com